Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Not Even Jim Simons’ Mathematical Models Could Pick Winning Stocks In Q3

Page 1 of 2

Renaissance Technologies, led by Jim Simons, disclosed a total of 3,196 positions in its latest 13F filing for the reporting period of June 30. The fund’s public equity portfolio was valued at $44 billion on that date. Our calculations showed that the hedge fund’s long positions in 1,567 stocks with a market cap of at least $1 billion delivered a weight average returns loss of 6.02% in the third quarter, dragging the quant fund’s stock pick returns down to a loss of 2.1% for the first three quarters of the year, using the same method of calculation. RenTec, which was founded in 1982, is legendary for its pioneering use of high frequency trading, exploiting inefficiencies in the stock market and delivering monster returns. RenTec delivered an average return of 71.8% before fees from 1994 through mid-2014. Previously, we analyzed the fund’s new tech positions, including Microsoft Corporation (NASDAQ:MSFT) and Alibaba Group Holding Ltd (NYSE:BABA). In this article, we’ll take a look at RenTec’s top five stocks, in terms of value, and study their third quarter returns.


We don’t just track the latest moves of hedge funds. We are, in fact, more interested in their 13F filings, which we use to determine the top 15 small-cap stocks held by the funds we track. We gather and share this information based on 16 years of research which showed that these 15 most popular small-cap picks have a great potential to outperform the market, beating the S&P 500 Total Return Index by nearly one percentage point per month in backtests, and easily beating the most popular large-cap picks of funds, which nonetheless get the majority of their collective capital. Why pay fees to invest in both the best and worst ideas of a particular hedge fund when you can simply mimic only the very best ideas of the best fund managers on your own? Since the beginning of forward testing in August 2012, the Insider Monkey small-cap strategy has outperformed the market every year, returning 118%, over two-times greater returns than the S&P 500 during the same period (see more details).

Jim Simons
Jim Simons
Renaissance Technologies

Colgate-Palmolive Company (NYSE:CL)

Shares Owned by RenTec (as of June 30): 12,590,800

Value of RenTec’s Shares (as of June 30): $823.6 million

Percentage of RenTec’s Public Equity Portfolio (as of June 30): 1.88%

Third Quarter Returns: -0.2%

Colgate-Palmolive Company (NYSE:CL) is a consumer products company, with a $58.82 billion market cap, which has suffered a 6.87% decrease in its stock price year-to-date. Recently, analysts at Deutsche Bank cut their price target for Colgate-Palmolive Company (NYSE:CL)’s stock to $65.00 from $74.00, and have a ‘Hold’ rating on it. Another investment firm that sees value in the stock is First Eagle Investment Management, which holds 4.81 million shares as of June 30.

Follow Colgate Palmolive Co (NYSE:CL)
Trade (NYSE:CL) Now!

Novo Nordisk A/S (ADR) (NYSE:NVO)

Shares Owned by RenTec (as of June 30): 14,087,000

Value of RenTec’s Shares (as of June 30): $771.4 million

Percentage of RenTec’s Public Equity Portfolio (as of June 30): 1.75%

Third Quarter Returns: -0.9%

Novo Nordisk A/S (ADR) (NYSE:NVO) had disappointing third quarter returns compared to its recent performance, though it still outperformed the market. The stock of the $114.4 billion market cap healthcare company, which is engaged in the development of pharmaceutical products, has increased by 30.4% year-to-date despite the third quarter setback. Novo Nordisk A/S (ADR) (NYSE:NVO) recently received approval from the Food and Drug Administration for two injectable insulin drugs, Tresiba and Ryzodeg. Tresiba, which is marketed in 30 countries, is expected to generate annual sales of $2.4 billion by 2020, according to Reuters. Another shareholder betting big on the company is Ken Fisher’s Fisher Asset Management, which holds 12.30 million shares as of the end of the second quarter.

Follow Novo Nordisk A S (NYSE:NVO)
Trade (NYSE:NVO) Now!

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!